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a b s t r a c t
Diverged 4000 years ago, inﬂuenza B virus has several important differences from inﬂuenza A virus,
including lower receptor-binding afﬁnity and highly restricted host range. Based on our prior structural
studies, we hypothesized that a single-residue difference in the receptor-binding site of hemagglutinin
(HA), Phe-95 in inﬂuenza B virus versus Tyr-98 in inﬂuenza A/H1–H15, is possibly a key determinant for
the low receptor-binding afﬁnity. Here we demonstrate that the mutation Phe95-Tyr in inﬂuenza B
virus HA restores all three hydrogen bonds made by Tyr-98 in inﬂuenza A/H1-15 HA and has the
potential to enhance receptor binding. However, the full realization of this potential is inﬂuenced by the
local environment into which the mutation is introduced. The binding and replication of the recombinant
viruses correlate well with the receptor-binding capabilities of HA. These results are discussed in relation
to the roles of Phe-95 in receptor binding and pathogenicity of inﬂuenza B virus.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza A and B viruses remain a major cause of morbidity
and mortality in humans. The entry of inﬂuenza virus into host cells
is mediated by hemagglutinin (HA), a major surface glycoprotein
of inﬂuenza A or B virus, via two distinct steps. The ﬁrst step is the
binding of HA to cell-surface sialic acid receptors at its distal globular
domain that initiates the endocytosis process. The second step
involves an extremely large-scale conformational change of HA at
its proximal stem domain that causes the fusion of endosomal
membrane with viral envelope, thus releasing the viral genetic
materials into host cytosols for replication.
Inﬂuenza A virus infects a wide range of hosts including humans,
avians, equines and swine (Skehel and Wiley, 2000; Steinhauer,
2010; Wiley and Skehel, 1987). Aquatic birds are the natural
reservoir for inﬂuenza A virus where 16 serologically different HA
subtypes have been discovered (Fouchier et al., 2005; WHO-
MEMORANDUM, 1980), and a new subtype H17 has been recently
found from little yellow-shouldered bats (Tong et al., 2012). Among
them, only inﬂuenza A viruses of H1, H2, and H3 HA subtypes have
been established in humans and caused seasonal inﬂuenza epi-
demics and all known pandemics, while other subtypes such as H5,
H6, H7 and H9 are believed to have potential for human pandemics
(Yen and Webster, 2009). The ability of inﬂuenza A virus to
efﬁciently infect human population is correlated with the high
afﬁnity of HA to Neu5Acα(2,6)Gal sialic acid receptors, also known
as human receptors, with a characteristic umbrella-like structural
topology (Srinivasan et al., 2008; Viswanathan et al., 2010a). The
other type of receptors, Neu5Acα(2,3)Gal, as frequently found in
bird intestines, are referred to as avian receptors. The receptors bind
to a shallow receptor-binding site at the globular domain of HA
formed by three key residues at the base that are absolutely
conserved among inﬂuenza A/H1–H15 HA glycoproteins: Tyr-98,
Trp-153, and His-183 (A/H3 HA numbering) (Wilson et al., 1981).
Different from inﬂuenza A virus, inﬂuenza B virus does not
have subtypes. Instead, currently circulating inﬂuenza B virus
belongs to either Yamagata lineage or Victoria lineage that
diverged from each other in early 1970 (Chen et al., 2007; Shen
et al., 2009). Most strikingly, inﬂuenza B virus has a very limited
host range, circulating almost exclusively among humans and seals
(Osterhaus et al., 2000). In addition, inﬂuenza B viruses were
found to have overall lower receptor-binding afﬁnities than
inﬂuenza A viruses (Matrosovich et al., 1993).
Our group has determined the crystal structures of inﬂuenza B
virus HA in various states (Ni et al., 2013; Wang et al., 2007, 2008). In
marked contrast to inﬂuenza A/H1–H15 HA that have Tyr-98,
inﬂuenza B virus HA has Phe-95 instead (based on the numbering
of inﬂuenza B/Hong Kong/8/73 (B/HK/73) HA) (Wang, 2010; Wang
et al., 2007, 2008). This is similar to the Phe-98 residue observed in
inﬂuenza A/H16–H17 HA proteins (Fouchier et al., 2005; Sun et al.,
2013; Tong et al., 2012; Zhu et al., 2013). When Tyr-98 is present, the
hydroxyl oxygen atom on its side chain makes one hydrogen bond
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with His-183 to stabilize the base of the receptor-binding site and
two additional hydrogen bonds with the Sia-1 moiety of the bound
receptors (Weis et al., 1988). The absence of the hydroxyl oxygen
atom on the side chain of Phe-95 in inﬂuenza B virus HA results in
the loss of all three hydrogen bonds (Wang et al., 2007), and is likely
responsible for the low binding afﬁnity of inﬂuenza B virus.
In this study, we examined the effects of the Phe95-Tyr
mutation at the levels of both recombinant protein and virus.
Although naturally occurring inﬂuenza B viruses generally have
Asn and Ser at HA1 194 and 196 respectively, making a glycosyla-
tion site at Asn194, this glycosylation site was frequently abolished
in egg-adapted variants (Gambaryan et al., 1999; Oxford et al.,
1990, 1991; Robertson et al., 1985, 1990; Saito et al., 2004; Schild
et al., 1983), and sporadic ﬁeld isolates (Ikonen et al., 2005;
Nakagawa et al., 2000), as a result of mutations at HA1 194 or
196 or both. Since this glycosylation site is located on the 190-helix
that forms the upper edge of the receptor-binding site (Ni et al.,
2013; Wang et al., 2007), we tested the mutation Phe95-Tyr on
inﬂuenza B virus HA with a glycosylation at HA1 194 (wild type) or
without (Asn194-Asp). The mutation was assessed on two
different backgrounds (B/Yamagata/73 and B/Lee/40 HA). Our data
demonstrate that the mutation Phe95-Tyr restores all three
hydrogen bonds made by Tyr-98 in inﬂuenza A/H3 HA and has
the potential to enhance receptor binding. However, the complete
realization of this potential is context dependent. The binding and
replication of the recombinant viruses correlate well with the
receptor-binding capabilities of their corresponding HA proteins.
These results are discussed in relation to the roles of HA Phe-95 in
receptor binding and pathogenicity of inﬂuenza B virus.
Results
Expression of recombinant wild-type and mutant inﬂuenza
B/Yamagata/73 HA
The ectodomains of the recombinant wild-type inﬂuenza
B/Yamagata/73 HA and its mutants (single mutants: Phe95-Tyr,
Asn194-Asp and double mutant Phe95-Tyr/Asn194-Asp) were
expressed in mammalian cell CV-1 using vaccinia virus system
(Blasco and Moss, 1995) and puriﬁed to high purity. For the
Asn194-Asp and Phe95-Tyr/Asn194-Asp mutants, the glyco-
sylation at HA1 194 was depleted in order to mimic the situation in
some ﬁeld isolates (Ikonen et al., 2005; Nakagawa et al., 2000) or
due to egg adaptation (Gambaryan et al., 1999; Oxford et al., 1990,
1991; Robertson et al., 1985, 1990; Saito et al., 2004; Schild et al.,
1983). Consequently, the molecular weights of the HA0 monomer
for these two mutants are about 3 kDa smaller than that of wild-
type HA as shown on SDS-PAGE (Fig. 1a). After using PNGase F to
remove the N-linked glycans, all the recombinant proteins exhibit
the same molecular weight on SDS-PAGE (Fig. 1b).
The Phe95-Tyr mutation enhances receptor-binding afﬁnity of
inﬂuenza B/Yamagata/73 HA
To investigate the impact of the Phe95-Tyr mutation on the
receptor binding capability of HA, we carried out a glycan micro-
array analysis on wild-type B/Yamagata/73 HA and its three
mutants (Fig. 2). Out of the more than 400 glycans on the
microarray chips, a total of 97 glycans showed signiﬁcant binding
(ﬂuorescence intensity45000) for at least one of the four protein
samples (Fig. 2). Clearly, wild-type HA has an overall weak binding
for the majority of glycans, however, it does exhibit an obvious
preference towards human-like Neu5Acα(2,6)Gal receptors
(Fig. 2a, in red color), which are abundantly found in human
upper respiratory tracts, the entry point of wild-type inﬂuenza B
virus. On the other hand, the mutation Asn194-Asp, with the loss
of the glycosylation at HA1 194, results in a preferential binding to
avian-like Neu5Acα(2,3)Gal receptors, with overall increased
ﬂuorescence intensities relative to the wild-type HA (Fig. 2b).
Compared to the wild-type HA, Phe95-Tyr HA shares the
same preference for human-like Neu5Acα(2,6)Gal receptors, but
with much higher ﬂuorescence intensities (Fig. 2c). In addition, the
binding is also signiﬁcantly improved for avian-like Neu5Acα(2,3)
Gal receptors (in green color), mixed Neu5Acα(2,3)/α(2,6)Gal
receptors (in blue color) and free sialic acids (in black color).
Fig. 1. SDS-PAGE analysis of recombinant proteins of wild-type inﬂuenza B/Yamagata/73 HA and its mutants. (a). Puriﬁed recombinant proteins. (b). Puriﬁed proteins treated
with PNGase F to remove the N-linked glycans. Shown are wild-type HA (Lane 1), mutant Phe95-Tyr (Lane 2), Asn194-Asp (Lane 3) and Phe95-Tyr/Asn194-Asp (Lane
4). The proteins are in uncleaved HA0 state.
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Similarly, compared to Asn194-Asp, the Phe95-Tyr/Asn194-
Asp mutant has signiﬁcantly enhanced binding signals to all types
of Neu5Ac-containing receptors (Fig. 2d). Furthermore, Phe95-
Tyr/Asn194-Asp exhibits substantial binding signals even for
Neu5Gcα(2,3)Gal (in dark green color), Neu5Gcα(2,6)Gal (in pur-
ple color) and Neu5Gcα(2,6)GlcNAc glycans (in cyan color)
(Fig. 2d). Interestingly, it also binds to several other glycans
(Fig. 2d, in gray color) including a Neu5Acα(2,8)-linked glycan
(#3) and non-sialic-acid glycans such as Galβ1–4GlcNAcβ1-
2Manα-Sp0 (#4) whose terminal residues resemble the cleavage
products of inﬂuenza NA (Supplemental Table S1).
To obtain a quantitative comparison, we performed dose-
dependent glycan binding assays using an avian-like Neu5Acα
(2,3)Gal receptor (3′SLN-LN) and a human-like Neu5Acα(2,6)Gal
receptor (6′SLN-LN) (Table 1). The calculated apparent dissociation
constants of wild-type and Phe95-Tyr HA are 5.8103 M and
3.5106 M for the 3′SLN-LN, 2.3104 M and 1.61011 M for
the 6′SLN-LN, respectively (Table 1). Thus, the wild-type HA binds
to 6′SLN-LN with 25 times higher afﬁnity than 3′SLN-LN.
Compared to the wild-type HA, the mutation Phe95-Tyr
enhances the binding for 3′SLN-LN and 6′SLN-LN by 103 and 107
times, respectively (Table 1).
The mutation Asn194-Asp has an apparent dissociation con-
stant of 4.51012 M for 3′SLN-LN, in contrast to the 7.5105 M
dissociation constant for 6′SLN-LN (Table 1). The loss of glycosyla-
tion at HA1 194–196 is frequently observed in egg-adapted
variants, indicating an advantage of doing so in order to adapt to
a Neu5Acα(2,3)Gal-enriched environment. Our quantitative data
reported here provide a molecular basis for this advantage: the
Asn194-Asp mutant has an 109 times higher afﬁnity for 3′SLN-
LN than the wild-type HA, while they share a similar afﬁnity for 6′
SLN-LN (Table 1).
Fig. 2. The mutation Phe95-Tyr promotes the binding of inﬂuenza B/Yamagata/73 HA protein to synthetic glycans in glycan microarray assays. The results of glycan
microarray assays are shown for (a) wild type, (b) Asn194-Asp, (c) Phe95-Tyr and (d) Phe95-Tyr/Asn194-Asp. Refer to Supplemental Table S1 for the full name of each
glycan.
Table 1
Equilibrium dissociation constants of recombinant wild-type inﬂuenza B virus HA and its mutants in binding to Neu5Acα(2,3)Gal and Neu5Acα(2,6)Gal receptor analogues.
HA
3′SLN-LNa 6′SLN-LNa
n K ′d R
2 n Kd′ R2
B/Yamagata/73
Wild type 0.4970.05 5.874.7103 M 0.9770.01 0.5970.01 2.370.2104 M 0.9770.01
Phe95-Tyr 0.8870.05 3.573.1106 M 0.99170.006 1.2770.03 1.671.01011 M 0.99570.001
Asn194-Asp 1.5070.02 4.571.71012 M 0.99770.001 0.8170.01 7.571.1105 M 0.98770.001
Phe95-Tyr/Asn194-Asp 1.30670.006 1.170.11011 M 0.99470.001 1.6570.03 3.371.81012 M 0.97170.002
B/Lee/40
Asn194-Asp 1.5170.06 8.775.51011 M 0.9870.01 0.97670.009 4.7470.01106 M 0.97870.001
Phe95-Tyr/Asn194-Asp 0.9970.06 2.471.7108 M 0.98970.006 1.13970.009 2.470.4109 M 0.9970.01
a The apparent dissociation constant ðK ′dÞ, co-operativity factor (n) and the R-square (R2) were obtained by ﬁtting the data to the linearized Hill equation in order to
quantitatively determine the relative binding afﬁnities of HA and its mutants. Their absolute values should be compared only in this context.
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As seen for the single mutant Phe95-Tyr, the double mutant
Phe95-Tyr/Asn194-Asp improves the binding for 6′SLN-LN
receptors by about 107 times compared to Asn194-Asp. Thus,
regardless of whether there is a glycosylation at HA1 194 (in the
case of Phe95-Tyr) or not (in the case of Phe95-Tyr/Asn194-
Asp), the mutation Phe95-Tyr consistently enhances the binding
of HA for 6′SLN-LN receptors by about 107 times. In contrast, while
the loss of the glycosylation at HA1 194 increases the afﬁnity for 3′
SLN-LN by 109 times (Asn194-Asp vs. wild type), no further
increase was seen for Phe95-Tyr/Asn194-Asp (Table 1). In other
words, in the double mutant Phe95-Tyr/Asn194-Asp, the
enhanced binding for 3′SLN-LN is mostly brought about by
Asn194-Asp, while the tighter binding for 6′SLN-LN is largely
the result of Phe95-Tyr. Our structural studies as reported in the
later section provide an explanation for this observation.
In ﬁtting the dose-dependent glycan binding assay data using
the linearized Hill equation, besides the apparent dissociation
constants, the values of the Hill coefﬁcient (n) were also obtained
(Table 1). A value of n 41.0 suggests a positive cooperativity in the
HA-glycan interactions, i.e., the binding of one receptor to
the receptor-binding site of one HA subunit may make it easier
for the binding of the second receptor to another HA subunit. On
the other hand, a value of no1.0 indicates a negative cooperativ-
ity. It is interesting to notice that comparing to the wild-type HA,
the Hill coefﬁcient values of Phe95-Tyr are almost doubled for
both 3′SLN-LN and 6′SLN-LN (Table 1). Similarly, relative to
Asn194-Asp, Phe95-Tyr/Asn194-Asp has also doubled its Hill
coefﬁcient for 6′SLN-LN. Consistent to their similar afﬁnity for 3′
SLN-LN, Asn194-Asp and Phe95-Tyr/Asn194-Asp have a simi-
lar Hill coefﬁcient.
The mutation Phe95-Tyr improves the binding of inﬂuenza
B/Yamagata/73 HA to cultured cell lines
We next tested whether the enhanced receptor-binding afﬁnity
of the Phe95-Tyr and Phe95-Tyr/Asn194-Asp mutants allows
inﬂuenza B/Yamagata/73 HA to bind host cells signiﬁcantly better.
To explore this, we developed a whole-cell-based ELISA assay that
quantitatively measures the amount of HA proteins immobilized
on cell culture monolayers through their association with cell-
surface receptors. Three established cell lines were used: MDCK1,
Baby hamster kidney (BHK21), and African green monkey kidney
(Vero). Although MDCK (ATCC catalog number: CCL-34) is a well-
established cell line for inﬂuenza A and B viruses, its derivative
MDCK1 (ATCC catalog number: CRL-2935) binds poorly to inﬂu-
enza B virus. Moreover, Vero cells have a high level of Neu5Acα
(2,3)Gal receptors and a low level of Neu5Acα(2,6)Gal receptors,
but still allow efﬁcient infection by inﬂuenza A or B virus
(Govorkova et al., 1996). On the other hand, BHK21 cells barely
have any detectable Neu5Acα(2,6)Gal receptors, and supports
poorly the growth of human inﬂuenza A and B viruses
(Govorkova et al., 1999; Milliken, 1967).
Overall, the wild-type inﬂuenza B virus HA has a very weak
binding to all three cell lines, with the strongest for Vero and
the weakest for BHK21 (Fig. 3a). The Asn194-Asp mutant has
a stronger binding to all three cell lines, with the strongest being
Vero cells (Fig. 3b). Phe95-Tyr, and especially Phe95-Tyr/
Asn194-Asp, signiﬁcantly improve the binding to all three cell
lines (Fig. 3c, d).
The B/Yamagata/73 HA Phe95-Tyr mutant competitively blocks the
binding and infection of inﬂuenza A virus
Since binding to cell-surface receptors is a prerequisite for
infecting host cells by inﬂuenza virus, we asked whether the
higher binding afﬁnity of the Phe95-Tyr and Phe95-Tyr/
Asn194-Asp mutants would allow them to compete more effec-
tively against infection caused by inﬂuenza virus. As a stringent
test, we used the A/Brisbane/10/2007 – like isolate TX-419 strain
belonging to inﬂuenza A/H3N2 virus that generally has a higher
binding afﬁnity for cell-surface receptors than inﬂuenza B virus
(Matrosovich et al., 1993). The test also included a “blank” where
Fig. 3. The mutation Phe95-Tyr enhances the binding of inﬂuenza B/Yamagata/73 HA protein to cultured cell lines MDCK1, BHK21 and Vero. (a) Wild type, (b) Asn194-
Asp, (c) Phe95-Tyr and (d) Phe95-Tyr/Asn194-Asp. The mutant Phe95-Tyr/Asn194-Asp showed the highest binding signals in all three cell lines. Its maximal
(saturated) chemiluminescence intensity with each cell line serves as the maximum for that cell line, and the binding signals are expressed as the percentage of the
maximum.
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no inﬂuenza A virus was added and a “positive control” where
only inﬂuenza A virus was added (Fig. 4). If the binding afﬁnity of
inﬂuenza B virus HA and/or its mutants is strong enough to
compete against inﬂuenza A virus for binding to cultured cells,
we expect to see a lower virus titer in the presence of these
recombinant proteins. Again we used MDCK1 for the assay, which
binds poorly by inﬂuenza B virus. Using ﬁve HAU of inﬂuenza A
virus as input to infect MDCK1 cells, at 24 h post-infection, the
“positive control” has a virus titer of about 64 HAU. With 400 μg
recombinant proteins, the wild-type has about two-fold inhibition
of inﬂuenza A virus over the “positive control” (Fig. 4), and the
Phe95-Tyr mutant displays eight-fold inhibition. Most strikingly,
while the Asn194-Asp single mutant exhibits very weak inhibi-
tion against the binding of inﬂuenza A virus, the mutant Phe95-
Tyr/Asn194-Asp completely blocks the infection of inﬂuenza A
virus with 400 μg (Fig. 4), 200 μg or even as low as 100 μg
recombinant protein. In conclusion, the higher binding afﬁnity of
the Phe95-Tyr and Phe95-Tyr/Asn194-Asp mutants for sialic
acid receptors does allow a much stronger competition against
inﬂuenza A virus infection.
Production of recombinant inﬂuenza B/Lee/40 viruses by reverse
genetics
In order to examine the impact of the Phe95-Tyr mutation on
inﬂuenza virus infection and replication, we generated recombi-
nant inﬂuenza B viruses by reverse genetics using all genes from
inﬂuenza B/Lee/40 virus (generous gifts from Dr. Yoshihiro
Kawaoka) following the previously reported protocol (Hatta and
Kawaoka, 2003). The mutations of Asn194-Asp and Phe95-Tyr
were introduced into the coding region of B/Lee/40 HA by site-
directed mutagenesis either individually or in combination. All the
viruses had correct sequences after one passage in MDCK cells.
However, in recombinant wild-type B/Lee/40 virus, Asn194 was
mutated to Asp194 or Ser194 after the second passage in MDCK
cells. This instability of Asn194 in recombinant wild-type B/Lee/40
virus when passaged in MDCK cells precluded a study of the wild-
type and Phe95-Tyr viruses. Consequently, the following studies
were only conducted on recombinant B/Lee/40 viruses harboring
Asn194-Asp or Phe95-Tyr/Asn194-Asp in the HA sequence.
The Phe95-Tyr mutation introduced into B/Lee/40 HA enhances
binding for human receptors but decreases binding for avian
receptors
The recombinant proteins in earlier sections of this study used
B/Yamagata/73 HA as the background. However, the recombinant
viruses generated by reverse genetics have B/Lee/40 HA instead.
These proteins share 94% sequence identity. There are two
noticeable differences between them: one is a glycosylation at
HA1 163 in B/Yamagata/73 HA but not in B/Lee/40 HA, while the
other is a glycosylation at HA1 230 in B/Lee/40 HA, but not in B/
Yamagata/73 HA (following B/HK/73 HA numbering). These glyco-
sylation sites are not at the receptor-binding site per se, but are
nearby. Therefore, we also expressed and puriﬁed recombinant
proteins of B/Lee/40 HA containing Asn194-Asp or Phe95-Tyr/
Asn194-Asp and tested their binding afﬁnity for synthetic
glycans (Table 1). Similar to the results of B/Yamagata/73 HA, the
Asn194-Asp mutation in B/Lee/40 HA exhibits 105 times
stronger binding for 3′SLN-LN than for 6′SLN-LN. However, the
introduction of Phe95-Tyr into B/Lee/40 HA containing the
Asn194-Asp mutation enhances the binding afﬁnity for 6′SLN-
LN by 2000 times, but at the same time decreases the binding
for 3′SLN-LN by 276 folds (Table 1).
Binding of recombinant B/Lee/40 viruses to different cell lines
To compare the binding capability of the recombinant viruses
to different cell lines, we ﬁrst labeled the viruses using Alexa 488
(Invitrogen), which were then used to bind to conﬂuent BHK21,
Vero, A549 and MDCK cells on 96-well plates that were pre-chilled
at 4 1C. The cell monolayer was overlaid with labeled viruses at a
multiplicity of infection (MOI) of 3 for 1 h at 4 1C. The incubation at
4 1C was to ensure that no NA activity was present, which was
conﬁrmed by using the substrate 2′-(4-methylumbelliferyl)-a-D-
N-acetylneuraminic acid (MUNANA) at 4 1C. The ﬂuorescence
obtained for Asn194-Asp virus to each cell line was expressed
as 100%. The Phe95-Tyr/Asn194-Asp virus exhibits 60–80%
binding signals relative to the Asn194-Asp virus (Fig. 5). The
about 20% higher binding of the Phe95-Tyr/Asn194-Asp virus to
MDCK cells, compared to Vero and BHK21 cells, agrees well with
the higher content of Neu5Acα(2,6)Gal receptors on MDCK cells
(Govorkova et al., 1996; Ito et al., 1997b) for which the recombi-
nant Phe95-Tyr/Asn194-Asp protein prefers (Table 1). However,
Fig. 4. The mutation Phe95-Tyr on inﬂuenza B/Yamagata/73 HA protein efﬁ-
ciently inhibits the binding of inﬂuenza A virus to MDCK1 cells. (a) and
(b) Comparison of inhibition efﬁciency by recombinant inﬂuenza B virus HA. The
“Blank” sample is the negative control where the MDCK1 cells grow under normal
condition in the binding inhibition assay. The “Positive” sample is the positive
control where the MDCK1 cells were infected with 5 HAU inﬂuenza A virus without
the addition of any recombinant inﬂuenza B virus HA proteins. The “Wild type”,
“Phe95-Tyr”, “Asn194-Asp” and “Phe95-Tyr/Asn194-Asp” samples represent
those wells where the MDCK1 cells were ﬁrst bound with 400 μg recombinant
proteins before the infection of inﬂuenza A virus. The titer was read as the highest
dilution where the red button was observed.
Fig. 5. Binding of recombinant inﬂuenza B/Lee/40 viruses to cultured cells. Alexa
488-labeled viruses were bound to chilled cells in 96-well plates at an MOI of 3 and
incubated at 4 1C for 1 h. The relative binding in each cell line is expressed as a
percentage of that of recombinant inﬂuenza virus that harbors Asn194-Asp HA.
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the Phe95-Tyr/Asn194-Asp virus does not bind to any of the
cultured cells at the same level as the Asn194-Asp virus.
Agglutination of erythrocytes by recombinant B/Lee/40 viruses
We then examined the ability of recombinant viruses to
agglutinate erythrocytes of different animal species, which are
known to contain different types, density and distribution of
glycans on the cell surface. Consistent with the picomolar dis-
sociation constant of the recombinant Asn194-Asp HA protein for
3′SLN-LN receptors, the Asn194-Asp virus binds to a higher titer
for chicken, turkey and guinea pig erythrocytes (containing mixed
α(2,3)- and α(2,6)-linked sialic acid receptors) than for sheep,
horse and bovine erythrocytes (containing predominantly α(2,6)-
linked sialic acid receptors) (Ito et al., 1997a; Medeiros et al., 2001;
Takemae et al., 2010) (Table 2). Its binding to horse erythrocytes is
particularly low, in agreement with the fact that horse erythro-
cytes contain 100% Neu5Gc (Suzuki, Matsunaga, and Matsumoto,
1985) that cannot be recognized by the Asn194-Asp protein on B/
Yamagata/73 HA (Fig. 2b). In sharp contrast, the Phe95-Tyr/
Asn194-Asp virus binds at a higher titer to sheep, horse and
bovine erythrocytes, consistent with the stronger binding of the
Phe95-Tyr/Asn194-Asp HA protein for Neu5Acα(2,6)Gal recep-
tors (in the case of sheep and bovine erythrocytes) (Table 1) and
for Neu5Gc-containing sialic acids (in terms of horse erythrocytes)
(Fig. 2d). Interestingly, by incubating the virus–erythrocyte mix-
tures at 37 1C for 2 h to allow the cleavage of sialic acids by viral
NA protein, the majority of Asn194-Asp virus is quickly eluted
from erythrocytes, while in marked contrast, the binding of the
Phe95-Tyr/Asn194-Asp virus hardly changes. After overnight
incubation at 37 1C, the Phe95-Tyr/Asn194-Asp virus is eluted
from most erythrocytes but remains bound to guinea pig and
horse erythrocytes at a signiﬁcant level (Table 2). These data
suggest that the activity of NA is not sufﬁciently high to keep up
with the strong binding of the Phe95-Tyr/Asn194-Asp HA, thus
a longer working time is needed.
Replication of recombinant B/Lee/40 viruses in MDCK cells and mice
We compared the replication capabilities of the recombinant
viruses in MDCK cell line that are known to contain both Neu5Acα
(2,3)Gal and Neu5Acα(2,6)Gal receptors (Govorkova et al., 1996;
Ito et al., 1997b). Relative to the titer of the Asn194-Asp virus
(at 2.8106 pfu/mL), the Phe95-Tyr/Asn194-Asp virus has a
comparable titer of 3.0106 pfu/ml (Table 3).
The replication capabilities of the recombinant viruses were also
tested in mice. By administering 104 PFU recombinant viruses
intranasally, the mice have an average viral titer of 2.2102 pfu/mL
for the Phe95-Tyr/Asn194-Asp virus, in marked contrast to the
titer of 2.7105 pfu/mL for the Asn194-Asp virus, indicating an
attenuation of 1000 folds for the former (Table 3). This attenuation
is in good agreement with the 276 times lower binding afﬁnity of the
Phe95-Tyr/Asn194-Asp protein, compared to Asn194-Asp, for
Neu5Acα(2,3)Gal receptors (Table 1) that are almost exclusively
found in mouse airway epithelial cells (Tang and Chong, 2009).
These data suggest that the observed differential replication of these
viruses in mice is likely resultant from the different binding afﬁnities
of their HA proteins to Neu5Acα(2,3)Gal receptors.
Structural basis for the effects of Phe95-Tyr on binding to receptors
In order to understand the effects of Phe95-Tyr on binding
to receptors, we determined the crystal structures of B/Lee/40
HA containing Phe95-Tyr/Asn194-Asp and its complexes with
human-like LSTc and avian-like LSTa receptor analogues to 2.53,
2.63 and 2.72 Å, respectively (Table 4). As noted earlier (Ni et al.,
2013), B/Yamanashi/98 HA differs signiﬁcantly from B/HK/73 HA in
the region of HA1 235–240. It appears that B/Lee/40 HA is also
different from B/HK/73 HA (Fig. 6a) but closely resembles B/
Yamanashi/98 HA (Fig. 6b). As expected, the extra hydroxyl oxygen
atom on the side chain of the introduced Tyr-95 mediates an extra
hydrogen bond (in magenta color) with His-191, one of the three
key residues constituting the receptor-binding site of inﬂuenza B
virus HA (Fig. 6a, b). Moreover, the interaction between the
receptor-binding site of HA and the bound receptor analogues,
LSTc and LSTa, is strengthened by the two additional hydrogen
bonds between the Sia-1 moiety and the hydroxyl oxygen atom of
Tyr-95 (Fig. 6c, d, in magenta color, Table 5). Thus, the mutation
Phe95-Tyr restores all three hydrogen bonds that the hydroxyl
oxygen atom of Tyr-98 makes in inﬂuenza A/H3 HA (Weis et al.,
1988). However, whether and how much this mutation enhances
the binding to human or avian receptors depends on the local
Table 2
Agglutination of erythrocytes by recombinant B/Lee/40 viruses under different conditionsa.
Erythrocytesb Agglutination by virus (HAU/50 mL)
4 1C, 2 h 4 1C, 2 h and 37 1C, 2 h 4 1C, 2 h and 37 1C, overnight
Asn194-Asp Phe95-Tyr/Asn194-Asp Asn194-Asp Phe95-Tyr/Asn194-Asp Asn194-Asp Phe95-Tyr/Asn194-Asp
cRBC 128 8 o2 8 o2 o2
tRBC 256 16 128 16 o2 2
gpRBC 128 16 o2 16 o2 16
sRBC 64 64 o2 32 o2 o2
hoRBC 4 64 o2 64 o2 32
bRBC 64 16 o2 16 o2 o2
Asialo cRBC o2 o2 o2 o2 o2 o2
a HAU were recorded at different time points after erythrocytes were incubated with virus for 2 h at 4 1C, then placed at 37 1C for 2 h, or placed at 37 1C overnight.
b cRBC, chicken red blood cell (RBC); tRBC, turkey RBC; gpRBC, guinea pig RBC; sRBC, sheep RBC; hoRBC, horse RBC; bRBC, bovine RBC. Asialo cRBC: cRBCs were treated
with Clostridium perfringens NA to remove sialic acids.
Table 3
In vivo and in vitro replication capabilities of recombinant B/Lee/40 viruses.
Mutations in HA MDCKa (pfu/mL) Mice lungsb (pfu/mL lung)
Asn194-Asp 2.870.2106 2.770.3105
Phe95-Tyr/Asn194-Asp 3.070.1106 2.271.7102
a MDCK cells were infected at an MOI of 0.1 and the titer was determined at
48 h post-infection.
b Mice were administered intranasally at 104 PFU, and lungs were harvested at
72 h post-infection. Titers are expressed as mean7standard deviation pfu/mL lung
lysates that were collected from four mice within each group.
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environment at and around the receptor-binding site (see
Discussion).
In contrast to the relatively higher position of the Sia-1 moiety
in the receptor-binding site of B/Yamanashi/98 HA (containing
Phe-95), the presence of Tyr-95 pulls the Sia-1 moiety deeper into
the receptor-binding site by a rotation of 181 (Fig. 6e). If every-
thing else is the same, the pull-down of Sia-1 by Tyr-95 could
result in substantial shifts in the positions of the following sugar
rings. To illustrate this point, we generated a modeled structure of
B/Lee/40 HA Asn194-Asp – LSTa by using the conformation of
LSTa in the B/Lee/40 HA Phe95-Tyr/Asn194-Asp – LSTa struc-
ture, but with the Sia-1 moiety at the higher position as observed
in B/Yamanashi/98 HA (Fig. 6f, in orange color). Clearly, compared
to the modeled B/Lee/40 HA Asn194-Asp – LSTa structure, the
LSTa in the B/Lee/40 HA Phe95-Tyr/Asn194-Asp extends closer
to the glycosylation at HA1 230 in the 240-loop (Fig. 6f, in cyan
color). This closer spatial location between the LSTa and the
glycosylation at HA1 230 may be responsible for the reduced
binding afﬁnity of B/Lee/40 HA Phe95-Tyr/Asn194-Asp for 3′
SLN-LN (Table 1).
Discussion
Phe95-Tyr increases the receptor-binding afﬁnity of recombinant
inﬂuenza B virus HA proteins
Comparing with inﬂuenza A virus, naturally occurring inﬂuenza
B virus has a lower binding afﬁnity for synthetic glycans and
natural receptors on cell surface (Matrosovich et al., 1993). Built
upon our previous structural studies of inﬂuenza B virus HA (Ni
et al., 2013; Wang, 2010; Wang et al., 2007), we noticed a critical
difference between the HA glycoproteins of inﬂuenza A and B
viruses at the base of the receptor-binding sites, Tyr-98 in
inﬂuenza A/H1–H15 HA versus Phe-95 in inﬂuenza B virus HA.
Given the absolutely conserved nature of Tyr-98 among inﬂuenza
A/H1–H15 HA proteins, we speculated that the presence of HA
Phe-95 might be responsible for the lower receptor-binding
afﬁnity of inﬂuenza B virus.
Here, by using recombinant B/Yamagata/73 HA proteins, we
demonstrated that Phe95-Tyr is able to enhance the binding
afﬁnity to synthetic glycans by up to 107 times (Fig. 2, Table 1), to a
level that is comparable to those of inﬂuenza A virus (dissociation
constants at picomolar range) (Jayaraman et al., 2011; Pappas
et al., 2010; Srinivasan et al., 2008; Viswanathan et al., 2010b).
Most signiﬁcantly, the mutation drastically enhances the binding
to three cultured cell lines (Fig. 3) and competitively blocks the
binding and infection by inﬂuenza A virus (Fig. 4). Similarly, in the
background of B/Lee/40 HA Asn194-Asp, the Phe95-Tyr muta-
tion also increases the binding afﬁnity for 6′SLN-LN by 2000
times (Table 1).
It is interesting to note that the small-to-large mutation of
Phe95-Tyr in our study can be accommodated in the receptor-
binding site of inﬂuenza B virus HA easily and enhances the
receptor-binding afﬁnity. In sharp contrast, the large-to-small
mutation of Tyr98-Phe on inﬂuenza A/H3 HA almost abolished
the binding of the virus to red blood cells, and the recombinant
Tyr98-Phe virus cannot infect mutant MDCK cells with a reduced
level of cell-surface sialic acids (Martin et al., 1998) and replicates
poorly in mice (Meisner et al., 2008). Since the hydroxyl oxygen
atom on the side chain of Tyr-98 makes one hydrogen bond within
the receptor-binding site and two additional ones with the sialic
acid receptors (Weis et al., 1988), it is likely that Tyr98-Phe
somehow distorts the receptor-binding site and/or substantially
weakens the receptor binding in inﬂuenza A/H3 HA. On the other
hand, the fact that wild-type inﬂuenza B virus HA can still bind to
sialic acid receptors and red blood cells, albeit at a lower afﬁnity,
suggests that the loss of the hydroxyl oxygen atom in Phe-95,
compared to a tyrosine residue, has been at least partially
compensated, probably by some small local structural adjustments
such as those found within the 240-loop and 140-loop (Wang
et al., 2007).
The impacts of glycosylations on the receptor binding of inﬂuenza
virus HA proteins
The different paths that LSTa and LSTc exit from the receptor-
binding site provide a plausible explanation for the mutational
Table 4
Data collection and reﬁnement statistics of inﬂuenza B/Lee/40 HA Phe95-Tyr/Asn194-Asp and its complexes with LSTc and LSTa.
Unliganded Complex with LSTc Complex with LSTa
Data collection statistics
Resolution range (Å) 44.63–2.53 (2.67–2.53) 47.46–2.63 (2.77–2.63) 48.91–2.72 (2.87–2.72)
Space group P21 2 21 P21 2 21 P21 2 21
Unit cell
a, b, c (Å) 83.7, 128.6, 211.2 83.6, 128.3, 211.8 83.6, 128.4, 211.7
α,β,γ(1) 90, 90, 90 90, 90, 90 90, 90, 90
Unique reﬂections 75,220 68,564 59,313
Multiplicity 7.4 (7.0) 5.3 (5.2) 6.6 (6.6)
Completeness (%) 97.9 (93.9) 100.0 (100.0) 95.7 (87.1)
Mean I/sigma(I) 13.1 (4.4) 11.5 (2.4) 13.7 (4.0)
Wilson B-factor (Å2) 33.8 40.9 34.9
Rmerge (%) 11.4 (48.3) 11.1 (49.9) 11.8 (49.1)
Reﬁnement statistics
Rcryst (%) 18.7 (23.6) 20.7 (27.7) 19.4 (24.8)
Rfree (%) 22.2 (27.8) 24.5 (33.3) 22.9 (28.0)
Number of atoms 12,678 12,547 12,583
Protein 11,653 11,603 11,651
Ligands 459 594 663
Water 566 350 269
RMSD
Bond length (Å)/angles (1) 0.003/0.75 0.007/0.77 0.007/0.84
Ramachandran plot
Favored, allowed (%) 97.4, 2.6 97.1, 2.9 97.2, 2.8
Average B-factor (Å2) 36.3 44.0 34.1
Statistics for the highest-resolution shell are shown in parentheses.
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effects of Asn194-Asp and Phe95-Tyr in this study. Since the
Neu5Acα(2,3)Gal receptor (LSTa) exits the receptor-binding site at
the N-terminus of the 190-helix and the terminal sugar rings
interact with Thr-196 in the absence of the glycosylation at HA1
194 (Fig. 6d), this glycosylation may severely interfere with the
binding of Neu5Acα(2,3)Gal receptors to the receptor-binding site.
The interference may be responsible for the only modest increase
in binding to Neu5Acα(2,3)Gal receptors by the Phe95-Tyr
mutation that introduces two strong hydrogen bonds with the
Sia-1 moiety, while the corresponding increase for Neu5Acα(2,6)
Gal receptors is 107 folds (Fig. 6d, Table 1). Therefore, the removal
of the glycosylation at HA1 194 in B/Yamagata/73 HA containing
Fig. 6. Structural analysis of inﬂuenza B/Lee/40 HA containing the Phe95-Tyr/Asn194-Asp mutant and its complexes with avian- and human-like receptor analogues.
(a) Superposition of the receptor-binding sites between inﬂuenza B/Lee/40 HA Phe95-Tyr/Asn194-Asp mutant (in cyan) and inﬂuenza B/HK/73 HA (PDB code: 3BT6) (in
yellow). B/HK/73 and B/Yamagata/73 HA differ by one residue, Asn vs. His at HA1 116. The glycosylation at HA1 163 in B/HK/73 HA is also shown. (b) Superposition of the
receptor-binding sites between B/Lee/40 HA Phe95-Tyr/Asn194-Asp (in cyan) and B/Yamanashi/98 HA (PDB code: 4M40) (in orange). (c) Complex of B/Lee/40 HA Phe95-
Tyr/Asn194-Asp (in yellow) with human-like receptor LSTc (in green). (d) Complex of B/Lee/40 HA Phe95-Tyr/Asn194-Asp (in yellow) with avian-like receptor LSTa
(in green). (e) Superposition of the Sia-1 in the complex structures with LSTa by B/Lee/40 HA Phe95-Tyr/Asn194-Asp (in cyan) and B/Yamanashi/98 HA (PDB code: 4M44)
(in orange). (f) LSTa in the receptor-binding sites of B/Lee/40 HA Phe95-Tyr/Asn194-Asp and Asn194-Asp. The structure of B/Lee/40 HA Asn194-Asp – LSTa is modeled
by using the conformation of LSTa in the B/Lee/40 HA Phe95-Tyr/Asn194-Asp – LSTa structure (in cyan), but with the Sia-1 moiety at the higher position as observed in
B/Yamanashi/98 HA (in orange). The glycosylation at HA1 230 in B/Lee/40 HA is also shown. In all panels, the hydrogen bonds are shown in dashed lines according to the
color of the corresponding structure. The hydrogen bonds formed by the hydroxyl oxygen atom of Tyr-95 are highlighted in magenta.
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either Asn194-Asp or Phe95-Tyr/Asn194-Asp relieves this
interference and yields picomolar dissociation constants for
Neu5Acα(2,3)Gal receptors (Table 1).
However, in the case B/Lee/40 HA, although the loss of the
glycosylation at HA1 194 results in a picomolar dissociation
constant for Neu5Acα(2,3)Gal receptors, the introduction of
Phe95-Tyr into this background reduces the binding afﬁnity for
Neu5Acα(2,3)Gal receptors. It appears that the presence of Tyr-95
pulls down the Sia-1 to a lower position via an 181 rotation, which
results in a closer spatial location of the terminal sugar rings of
LSTa with the glycosylation at HA1 230 that is unique to B/Lee/40
HA (Fig. 6f). Thus, in addition to their recognized roles in
modulating antigenicity of inﬂuenza B virus (Nakagawa et al.,
2000, 2004; Wang et al., 2008), glycosylations at or near the
receptor-binding site of inﬂuenza B virus HA also inﬂuence the
receptor-binding afﬁnity and preference of the virus. This is
reminiscent of the glycosylation at HA1 158 of inﬂuenza A/H5
HA where its removal contributes to the completely switched
binding to human receptors (Imai et al., 2012; Tharakaraman et al.,
2013).
The roles of receptor binding of HA in inﬂuenza B virus pathogenicity
Recent studies on inﬂuenza A virus have demonstrated that
manipulating receptor-binding avidity is an important tool that
inﬂuenza A virus uses in response to neutralization imposed by
neutralizing antibodies, which seems to drive antigenic drift
(Hensley et al., 2009). Moreover, a single-nucleotide change in
the coding sequence of inﬂuenza A/H1 HA increased its binding
afﬁnity for human receptors, corrected the low receptor afﬁnity of
the ﬁeld isolate and led to efﬁcient airborne transmission in ferrets
(Jayaraman et al., 2011). These and other studies (Maines et al.,
2009; Pappas et al., 2010; Viswanathan et al., 2010b) suggest that
the binding afﬁnity of HA to receptors is an important determinant
for inﬂuenza A virus infectivity.
The lack of reservoirs of inﬂuenza B virus outside of human
population is believed to be one of the major reasons that
inﬂuenza B virus does not undergo antigenic shift, a molecular
evolutionary mechanism that is responsible for almost all known
human pandemics caused by inﬂuenza A virus (Gamblin and
Skehel, 2010; Skehel and Wiley, 2000; Steinhauer, 2010; Wang,
2010; Wiley and Skehel, 1987). It remained an open question
whether there exists a correlation between the limited host range
and the lower receptor binding afﬁnity of HA of naturally occur-
ring inﬂuenza B virus. Most recently, Palese and co-workers
published an interesting study in which the ectodomain of
inﬂuenza A/H1 HA was used to replace that of inﬂuenza B virus
HA in the backbone of inﬂuenza B virus. In marked contrast to the
wild-type inﬂuenza B virus, the chimeric inﬂuenza B virus with
inserted A/H1 HA resulted in temporary but signiﬁcant weight loss
in infected mice (Hai et al., 2011), suggesting that the stronger
receptor binding of inﬂuenza A/H1 HA has enhanced the patho-
genicity of the recombinant inﬂuenza B virus in which it resides.
The enhanced receptor binding afﬁnity of inﬂuenza B virus HA
upon a single Phe95-Tyr mutation at the receptor-binding site
provides a plausible explanation for the very limited host range
displayed by inﬂuenza B virus. As suggested in previous studies
(Martin et al., 1998), a sufﬁcient density of cell-surface sialic acids
with a weaker receptor-binding HA or a lower than optimal
density of sialic acids with a stronger receptor-binding HA are
both viable combinations for effective inﬂuenza infection. Thus,
the weaker receptor binding of wild-type inﬂuenza B virus HA
likely imposes a much higher demand for the “perfect” glycan
composition on the surface of target cells in a given host, thus the
virus may only infect hosts satisfying such a strict requirement.
A single Phe95-Tyr mutation was able to promote the binding
afﬁnity of inﬂuenza B/Yamagata/73 HA to a comparable level as
that of inﬂuenza A virus HA, regardless of human or avian-like
receptors, thus enabling its efﬁcient binding to three cultured cell
lines containing a varied range of glycan composition for which
the wild-type HA binds very poorly. While it is not known when,
how and why inﬂuenza B virus HA acquired Tyr95-Phe mutation
in the course of evolution, it is likely that some or all of the other
viral proteins of inﬂuenza B virus have undergone concomitant
changes, including a delicate balance between HA and NA (Mitnaul
et al., 2000). In addition, inﬂuenza viral infection is a complex
process involving a myriad of host factors (Brass et al., 2009; Hao
et al., 2008; Karlas et al., 2010; Konig et al., 2010; Li et al., 2011;
Shapira et al., 2009; Sui et al., 2009; Watanabe et al., 2010). While
our data revealed the striking importance of a single-residue
mutation at the receptor-binding site to the receptor binding
afﬁnity of inﬂuenza B virus HA, further studies are needed in
order to illustrate its implication to pathogenicity and evolution of
inﬂuenza B virus and co-evolution of HA with other viral proteins.
Table 5
Hydrogen bonding interactions of B/Lee/40 HA Phe95-Tyr/Asn194-Asp mutant with bound LSTc and LSTa receptor analogues.
Receptor Interaction pair B/Lee/HA Phe95-
Tyr/Asn194-Asp distance (Å)
Interaction pair B/Yamanashi/HA –LSTa
(PDB code: 4M44)
LSTc LSTa distance (Å)
Sia-1 O1A……Ser140 OG 3.3 3.2 O1A……Ser140 OG 3.4
O1A……Gly141 N 2.4 2.6 O1A……Gly141 N 2.8
O1B……Ser140 OG 2.9 2.8 O1B……Ser140 OG 2.9
O1B……Gln239 NE2 2.6 2.7 O1B……Gln239 NE2 2.8
O1B……Gln239 OE1 3.2 3.2 O1B……Gln239 OE1 3.3
O4………Thr139 O 3.5 3.6 O4………Thr139 O 3.4
N5………Thr139 O 3.0 3.0 N5………Thr139 O 3.3
O7………Arg200 NH2 2.7 2.5 O7………Asn200 –
O8………Tyr95 OH 3.1 3.3 O8………Phe95 –
O8………Gln239 OE1 3.0 2.9 O8………Gln239 OE1 3.1
O9………Tyr95 OH 3.3 3.3 O9………Phe95 –
O9………Asp193 OD2 2.6 2.5 O9………Asp193 OD2 2.7
O9………Gln197 NE2 3.5 – O9………Gln197 –
O9………Ser240 OG 3.3 3.5 O9………Ser240 OG 3.1
O10……..Lys136 – – O10……..Arg136 NH2 2.9
Gal-2 O3………Lys238 O 2.8 – O3………Pro238 –
O4………Lys238 O 3.1 – O4………Pro238 –
O6………Lys238 – 2.7 O6………Pro238 O 2.9
Glc-5 O2………Thr196 OG1 – 3.0 O2………Thr196 –
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Materials and methods
Cells
All cells were maintained at 37 1C in 5% CO2 incubator. 293 T,
A549, BHK21, CV-1 and Vero cells were maintained in Dulbecco's
Modiﬁed Eagle Medium (DMEM) with 10% fetal bovine serum
(FBS) and 1% penicillin–streptomycin. MDCK and MDCK1 cells
were maintained in Eagle's minimal essential medium (EMEM)
with 10% FBS and 1% penicillin–streptomycin. All cell lines were
purchased from ATCC.
Cloning, expression and puriﬁcation of inﬂuenza B virus HA and its
mutants
The HA cDNA of inﬂuenza B/Yamagata/73 and B/Lee/40 viruses
are kind gifts from Dr. Peter Palese and Dr. Yoshihiro Kawaoka,
respectively. Their ectodomains (HA1 1–342 with HA2 1–176) were
separately cloned to pRB21 plasmid (a kind gift from Dr. Bernard
Moss) to allow the expression in vaccinia systems (Blasco and
Moss, 1995). Site-directed mutagenesis was used to make the
Phe95-Tyr, Asn194-Asp and Phe95-Tyr/Asn194-Asp mutants
(Agilent Technologies). All the mutant constructs were fully
sequenced. The recombinant vaccinia viruses were generated by
infecting CV-1 cells with vRB12 and then transfected with pRB21
vector containing HA or its mutants (Blasco and Moss, 1995).
Protein expression and puriﬁcation followed the same protocol as
previously published (Ni et al., 2013).
Deglycosylation of HA
Puriﬁed HA protein was ﬁrst denatured in glycoprotein dena-
turing buffer at 95 1C for 10 min. The denatured protein was
treated with peptide-N-glycosidase F (PNGase F) (New England
Biolabs) with 1% NP-40 at 37 1C for 1 h to cleave the N-linked
glycans. The reaction products were visualized by SDS-PAGE.
Glycan microarray analysis
The binding proﬁles of puriﬁed HA and its mutants to different
glycans were determined by the Consortium of Functional Glyco-
mics (www.functionalglycomics.org) using version 4.1 glycan
microarray, which contains 465 glycan structures in replicates of
six. The HA proteins were ﬁrst incubated with anti-penta His
antibody (Qiagen) and Alexa488-labeled anti-mouse IgG (Invitro-
gen) on ice for 30 min. The ﬁnal concentration of HA proteins used
in the assay was 200 μg/mL. The protein complex was then
applied to a freshly hydrated glycan microarray under a cover slip
and the ﬂuorescence signals were recorded. As previously demon-
strated (Stevens et al., 2006), the success of the glycan array
depends on the use of the secondary ﬂuroscent anti-mouse IgG
antibody that can bind up to four HA trimers (thus having up to 12
glycan binding sites). This cooperative nature of the interaction
enhances the binding avidity and the binding signals. The glycans
with a signal of 5000 relative ﬂuorescence unit (RFU) or higher
for any of HA or its mutants are shown in Fig. 2 and listed in
Supplemental Table S1.
Dose-dependent glycan binding assay
To characterize the receptor binding afﬁnities of HA and its
mutants, biotinylated 3′SLN-LN and 6′SLN-LN from the Consor-
tium of Functional Glycomics were used in the dose-dependent
glycan binding assay (Srinivasan et al., 2008). LN represents
lactosamine (Galβ1–4GlcNAc), 3′SLN and 6′SLN represent Neu5-
Acα(2,3) and Neu5Acα(2,6) linked to LN, respectively. The
different glycans were ﬁrst diluted to 2.4 μM and loaded to the
streptavidin-coated high binding capacity 384-well plates (Pierce),
followed by incubation at 4 1C overnight. Excessive glycans were
removed by washing with phosphate-buffered saline (PBS) for
three times. The pre-complex of HA, mouse anti-His antibody
(0.2 mg/mL, Sigma) and anti-mouse-IgG antibody (2 mg/mL,
Sigma) was prepared at a molar ratio of 4:2:1. The mixture was
incubated on ice for 20 min, and the pre-complex was diluted to
the expected concentration with 1% bovine serum albumin (BSA)
in PBS. Each glycan-coated well was then loaded with 50 μL of the
HA pre-complex and incubated at room temperature for 2 h
followed by wash with 0.05% Tween-20 in PBS to remove any
unbound pre-complex. The Amplex Red Peroxidase Assay kit
(Invitrogen) was used to measure the binding signal based on
the horseradish peroxidase (HRP) activity. Negative controls,
where no pre-complexes were loaded in those wells, were
included for each glycan and the assays were performed in
triplicates. The linearized Hill equation was used to ﬁt the data
(Srinivasan et al., 2008).
Cell-based ELISA assay
In order to compare the binding of recombinant HA and its
various mutants to different types of cells, cell-based ELISA assay
was carried out with three cultured cell lines: MDCK1, BHK21 and
Vero. The conﬂuent cell monolayer in white 96-well Falcon plate
(BD Biosciences) was ﬁrst washed with Dulbecco's PBS (DPBS,
Invitrogen) and various amounts of HA or its mutants diluted with
1% BSA in DPBS was added to different wells, complete DMEM
(0.2% BSA, 25 mM Hepes in DMEM) was added to bring all the
wells to the same volume. The plate was incubated at room
temperature for 1 h. The supernatant was removed and each well
was washed with DPBS for three times and then 100 μL 3.7%
formaldehyde diluted in DPBS was added and incubated at room
temperature for 10 min. The ﬁxative was removed and wells were
washed with PBST (0.1% Triton X-100 in PBS) for three times. The
wells were then blocked with 10% FBS for 1 h at room temperature
followed by incubation with primary antibody (mouse anti-His
antibody, Sigma, 1:4000 dilution with 1% BSA in PBST) for 1 h at
room temperature. The wells were then washed three times with
PBST and ﬁnally incubated with secondary antibody (HRP-
conjugated anti-mouse-IgG, Sigma, dilution 1:40,000) for 1 h at
room temperature. After washing with PBST, the binding signal
was measured with ECL reagent (Amersham). All the assays were
performed in triplicates.
Binding inhibition assay in MDCK1 cells
MDCK1 cells were seeded at appropriate concentration in 96-
well plate one day before to achieve 100% conﬂuency when the
assays were performed. The cell monolayer was washed with DPBS
twice and thenwith complete DMEM once. Various amounts of HA
were loaded into different wells and complete DMEM was added
to bring all the wells to the same volume. After the plate was
incubated at room temperature for 1 h, 5 hemagglutination units
(HAU) of inﬂuenza A/Brisbane/10/2007 – like isolate TX 419 virus
and TPCK-trypsin (ﬁnal concentration of 2 μg/mL, Worthington)
were added to wells and the plate was incubated at 37 1C for an
additional hour (with 5% CO2). The supernatant was removed and
the wells were washed twice with complete DMEM. Finally, each
well was loaded with 100 μL complete DMEM with 2 μg/mL TPCK-
trypsin. After 24 h of infection, the supernatant was centrifuged
(300 g, 15 min) to pellet the cellular debris and used for the
standard hemagglutination assay with 1% human red blood cells.
All the assays were performed in triplicates.
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Reverse genetics and virus stock preparation
The plasmids for reverse genetics of inﬂuenza virus B/Lee/40
were generous gifts from Dr. Yoshihiro Kawaoka. Site-directed
mutagenesis was used to introduce the Phe95-Tyr, Asn194-Asp
and Phe95-Tyr/Asn194-Asp mutants into the gene of B/Lee/40
HA (Agilent Technologies). Co-cultures of 293 T and MDCK in
DMEM with 10% FBS were plated one day before. Two microliter
of TransIT-LT1 (Mirus Bio LLC) was used per 1 μg plasmid to make
the DNA–lipid complex. The DNA–lipid mixture was added to the
293 T-MDCK co-culture and the plate was incubated at 33 1C. At
16 h post-transfection, the medium was removed and cell mono-
layer was washed twice with DMEM. Fresh DMEM with 1 μg/mL
trypsin was added and the plate was further incubated for 48 h.
For virus with Phe95-Tyr or Phe95-Tyr/Asn194-Asp in HA,
1 μg/mL neuraminiase (NA) from Clostridium perfringens (Sigma)
was added to accommodate the increased binding afﬁnity of HA.
Viruses prepared by reverse genetic were then plaque-puriﬁed
and propagated twice in MDCK cells as follows. MDCK monolayer in
T-75 ﬂask after overnight incubation was washed with EMEM for
three times, followed by infection of 1 mL virus at room temperature
with occasional gentle rocking. After 1 h, the innoculum was
removed and 30 mL EMEM containing 1 μg/mL TPCK-trypsin was
added. The cells were incubated at 33 1C for 72 h until at least 70%
cells showed cytopathic effect. The supernatant was clariﬁed at
2600 g for 5 min, and laid over a 25% sucrose cushion in NTE buffer
(100 mM NaCl, 1 mM EDTA, 10 mM Tris–HCl, pH 7.4). The virus was
concentrated by ultracentrifugation at 30,000 rpm for 3 h at 4 1C. The
virus pellet was re-suspended in NTE buffer, aliquoted, and stored at
80 1C. The puriﬁed viruses were thawed before each use, and the
titer was determined with standard techniques.
The work on recombinant inﬂuenza B viruses was carried out
in Biosafety Level 2 plus facility located in Room 244E at Baylor
College of Medicine.
Sequencing of virus stocks
The virus stocks were sequenced to conﬁrm the desired
mutation in HA gene. QIAamp viral RNA kit (Qiagen) was used to
extract the viral RNA. The HA gene was ampliﬁed with primers
using Onestep RT-PCR kit (Qiagen) and sequenced. The viruses
with Phe95-Tyr, Asn194-Asp and Phe95-Tyr/Asn194-Asp all
had the expected sequences in HA. However, the wild-type virus
exhibited different behaviors. It had the expected Asn194 after one
passage in MDCK cells, but the glycosylation site at HA1 194–196
was quickly lost after the second passage in MDCK cells (Asn194
was mutated to Asp194 in ﬁve out of six sequenced viruses, and to
Ser194 in the other sequenced virus). Because Asn194 was not
stable in MDCK cells, only viruses with Asn194-Asp and Phe95-
Tyr/Asn194-Asp in HA were used in our subsequent studies.
Binding assay of recombinant viruses
The binding of ﬂuorescently labeled viruses to different cell
lines was performed following a previous report (Bradley et al.,
2011). First, 50 μL virus was incubated with 25 μg Alexa 488
(Invitrogen) in the presence of 0.1 M NaHCO3 (pH 9.0) for 1 h at
37 1C. The excessive Alexa 488 was then removed by dialysis
against PBS with 1 mM EDTA overnight at 4 1C using Slide-A-Lyzer
MINI Dialysis Devices (7 K MWCO, Thermo Scientiﬁc). The labeled
viruses were then used to bind conﬂuent BHK21, Vero, A549 and
MDCK cells on 96-well plates that were pre-chilled at 4 1C for 1 h.
The cell monolayer was overlaid with labeled viruses for 1 h at
4 1C, washed with PBS for three times, and read by FLUOstar
Omega (BMG LABTECH) using excitation and emission at 485 nm
and 528 nm, respectively. The binding assays were performed in
triplicates.
Replication of recombinant viruses in MDCK and mice
We compared the replication ﬁtness of recombinant viruses in
MDCK and mice. For replication of recombinant viruses in MDCK,
cell monolayer was infected with viruses at an MOI of 0.1. The
supernatant was harvested at 48 h post-infection.
For the replication in mice, six to eight-week old female BALB/C
mice (Charles River Laboratories) were administered intranasally
with 104 PFU recombinant viruses harboring Asn194-Asp or
Phe95-Tyr/Asn194-Asp HA, or with sterile PBS as negative
controls (four mice per group). At 72 h post-infection, mice from
each group were euthanatized; lungs were collected and imme-
diately frozen on dry ice, and stored at –80 1C. The frozen lungs
were later thawed, homogenized in 1 mL cold PBS, and clariﬁed by
centrifugation at 4 1C. Virus titers in the clariﬁed lung lysates were
determined by plaque assay using MDCK cells. For plaque assay
with Phe95-Tyr/Asn194-Asp virus, the plaques were of rod-like
shape. To get round-shaped plaques, 1 μg/mL Clostridium perfrin-
gens NA was added.
The mice work was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of Laboratory
Animals of the National Institutes of Health. The protocol was
approved by the Institutional Animal Care and Use Committee of
Baylor College of Medicine (Protocol Number: AN-856). All efforts
were made to minimize suffering.
Expression, puriﬁcation, crystallization and structure determination
of Phe95-Tyr/Asn194-Asp mutant of B/Lee/40 HA
The gene corresponding to the ectodomain of the Phe95-Tyr/
Asn194-Asp mutant of inﬂuenza B/Lee/40 HA was ampliﬁed and
inserted into pRB21 vector for expression. The puriﬁed protein was
concentrated to 15 mg/mL for crystallization. Crystals were
obtained by hanging drop vapor diffusion method at 290 K in
the reservior solution of 0.1 M succinic acid (pH 7.0) and 12%
PEG3350. A ﬁnal concentration of 25% glycerol was included in the
reservior solution as the cryoprotectant. The crystals were also
soaked in 10 mM avian-like receptor analogue LSTa or human-like
receptor analogue LSTc (Carbosynth) overnight. The crystals were
ﬂash-frozen in liquid nitrogen and X-ray diffraction data collection
was carried out at 100 K at Sector 21 (LS-CAT) at the Advanced
Photon Source, Argonne National Laboratory, U.S.A. The diffraction
data were processed as previously described (Ni et al., 2013). Five
percents of unique reﬂections were randomly selected as the test set
for monitoring the Rfree-factors in the reﬁnement. The inﬂuenza
B/Yamanashi/98 HA structure (Protein Data Bank accession code:
4M40) was used as the search model for molecular replacement, and
one copy of the HA trimer was found by PHENIX (Adams et al., 2010).
The molecular replacement solution was further built and reﬁned by
PHENIX. The model and map were viewed in COOT (Emsley and
Cowtan, 2004) for manual adjustment.
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